(1888PressRelease)
September 10, 2008 - Nantes, France – IN CELL ART, a biotechnology company involved in macromolecular drug (siRNA, DNA, proteins) delivery systems, has announced that the company has entered into a research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, to evaluate IN CELL ART nanocarriers’ technologies in the context of Sanofi Pasteur’s vaccines programme. Convincing results arising from such studies should lead to the continuation of IN CELL ART nanocarriers’ evaluation in Sanofi Pasteur’s new vaccines development.
IN CELL ART offers a range of biotechnology development services. The French company has expertise in antibody generation using genetic immunisation, allowing for the rapid synthesis of antibodies to any gene-specific antigen. This technology is particularly suitable for screening applications, which lead to the identification of antibodies of therapeutic interest.
IN CELL ART is also pursuing highly promising approaches in the field of DNA-based therapeutic and prophylactic vaccines, with successful studies in animal models of cancers and infectious diseases. IN CELL ART works in partnership with pharmaceutical and biotechnology companies and grants licences for its vaccine formulation.
With ongoing R&D programmes in the fields of oncology, as well as cardiovascular and anti-infectious diseases, IN CELL ART also works closely with companies that are active in the development of RNAi therapeutic products for interference with the expression of targeted disease-associated genes. Besides, IN CELL ART works with companies involved in the development of therapeutic proteins for the improvement of pharmacokinetics. In both these areas, IN CELL ART grants licences for its nanocarriers.
Finally, IN CELL ART is commercializing ICAFectin®441 and ICAFectin®442, which are DNA and siRNA transfection reagents for primary and stem cells.
About IN CELL ART
IN CELL ART, which is headquartered in Nantes (in western France), is a biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organised on a nanometric scale, which enables them to cross the cell barrier efficiently and safely.
IN CELL ART is a privately held company, which was founded in 2005. It is a member of the Atlantic Biotherapies high-tech cluster of biotechnology companies in western France. For further information, please go to: www.incellart.com.
###
